All In Biotech

Drug Trial Radar · NCT07881224

A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult Subjects

A Phase 1, Non-randomized, Fixed-sequence, Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Mar 9, 2027

Study completion Mar 9, 2027

Sponsor

Lead sponsor
Basilea PharmaceuticaIndustry
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority
First posted
Oct 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, fixed-sequence, multiple-dose study in approximately 42 healthy adult participants. The study will be conducted in two parts. Part 1 will evaluate the effect of fosmanogepix, through exposure to its active moiety manogepix, on selected CYP enzymes and on the concentration-QT interval corrected for heart rate (QTc). Part 2 will evaluate the effect of manogepix on CYP2C8 and on selected drug transporters. The maximum study duration will be approximately 13.5 weeks for participants in Part 1 and approximately 12 weeks for participants in Part 2.

Conditions

  • Healthy Adult Participants

Interventions

  • FosmanogepixDrug

    Fosmanogepix will be administered as an intravenous infusion or as an oral tablet

  • PlaceboOther

    Placebo will be administered as an intravenous infusion or as an oral tablet

  • The medicine cocktail (caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan and midazolam)Other

    The medicine cocktail will be administered as tablet, capsule, or drink to be swallowed

  • Probe substrates (repaglinide, rosuvastatin, and digoxin)Other

    Probe substrates will be administered as oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Maximum Plasma Concentration (Cmax) of the medicine cocktail when administered alone or in combination with manogepix at steady stateTime frame: At Day 1 and Day 22
  2. Part 1: Area under the concentration-time curve (AUC) of the medicine cocktail when administered alone or in combination with manogepix at steady stateTime frame: At Day 1 and Day 22
  3. Part 2: Maximum Plasma Concentration (Cmax) of probe substrate cocktail when administered alone or in combination with manogepix at steady stateTime frame: From Day 1 to Day 20
  4. Part 2: Area under the concentration-time curve (AUC) of probe substrate cocktail when administered alone or in combination with manogepix at steady stateTime frame: From Day 1 to Day 20

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON Early Clinical & Bioanalytical Solutions

    Groningen, Netherlands, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.